Edgewise Therapeutics, Inc.
EWTX
$14.60
$0.302.10%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -1.63% | 0.35% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -7.29% | 0.92% | |||
| Operating Income | 7.29% | -0.92% | |||
| Income Before Tax | 11.48% | -2.86% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 11.48% | -2.86% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 11.48% | -2.86% | |||
| EBIT | 7.29% | -0.92% | |||
| EBITDA | 7.39% | -1.07% | |||
| EPS Basic | 19.77% | -2.44% | |||
| Normalized Basic EPS | 19.74% | -2.41% | |||
| EPS Diluted | 19.77% | -2.44% | |||
| Normalized Diluted EPS | 19.74% | -2.41% | |||
| Average Basic Shares Outstanding | 10.31% | 0.43% | |||
| Average Diluted Shares Outstanding | 10.31% | 0.43% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||